These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32555131)

  • 1. Effects of Combined Bushen Zhichan Recipe and Levodopa in a Rodent Model of Parkinson Disease: Potential Mechanisms.
    Li W; Gao H; Li W
    Med Sci Monit; 2020 Jun; 26():e922345. PubMed ID: 32555131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic study of the anti-excitatory amino acid toxicity of Bushen Zhichan decoction for Parkinson's disease based on the transcriptional regulation of EAAT1 by YY1.
    Liu L; Tian X; Li W
    J Ethnopharmacol; 2024 May; 325():117857. PubMed ID: 38350506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of bushen yanggan recipe on nigrostriatal function in parkinsonian model rats after long-term levodopa treatment].
    Cai DF; Chen XQ; Gao Y
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2002 Jan; 22(1):43-6. PubMed ID: 12585172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-asarone and levodopa co-administration protects against 6-hydroxydopamine-induced damage in parkinsonian rat mesencephalon by regulating autophagy: down-expression Beclin-1 and light chain 3B and up-expression P62.
    Huang LP; Deng MZ; He YP; Fang YQ
    Clin Exp Pharmacol Physiol; 2015 Mar; 42(3):269-77. PubMed ID: 25424835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
    Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
    Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
    Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
    Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
    Zhang K; Chammas C; Soghomonian JJ
    Neuroscience; 2015 Sep; 303():586-94. PubMed ID: 26188284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xiaoyaosan exerts antidepressant-like effects by regulating the functions of astrocytes and EAATs in the prefrontal cortex of mice.
    Liu Y; Ding XF; Wang XX; Zou XJ; Li XJ; Liu YY; Li J; Qian XY; Chen JX
    BMC Complement Altern Med; 2019 Aug; 19(1):215. PubMed ID: 31412844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electroacupuncture Therapy Ameliorates Motor Dysfunction via Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor in a Mouse Model of Parkinson's Disease.
    Pak ME; Ahn SM; Jung DH; Lee HJ; Ha KT; Shin HK; Choi BT
    J Gerontol A Biol Sci Med Sci; 2020 Mar; 75(4):712-721. PubMed ID: 31644786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats.
    Jonkers N; Sarre S; Ebinger G; Michotte Y
    Eur J Pharmacol; 2000 Nov; 407(3):281-91. PubMed ID: 11068024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered melatonin MT
    Kang NH; Carriere CH; Bahna SG; Niles LP
    Brain Res; 2016 Dec; 1652():89-96. PubMed ID: 27693415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.
    Salama M; Ellaithy A; Helmy B; El-Gamal M; Tantawy D; Mohamed M; Sheashaa H; Sobh M; Arias-Carrión O
    CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):836-43. PubMed ID: 23198691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
    Mantas I; Yang Y; Mannoury-la-Cour C; Millan MJ; Zhang X; Svenningsson P
    Neuropharmacology; 2020 Jan; 162():107829. PubMed ID: 31666199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axin-2 knockdown promote mitochondrial biogenesis and dopaminergic neurogenesis by regulating Wnt/β-catenin signaling in rat model of Parkinson's disease.
    Singh S; Mishra A; Mohanbhai SJ; Tiwari V; Chaturvedi RK; Khurana S; Shukla S
    Free Radic Biol Med; 2018 Dec; 129():73-87. PubMed ID: 30176346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process.
    Ferrario JE; Delfino MA; Stefano AV; Zbarsky V; Douhou A; Murer MG; Raisman-Vozari R; Gershanik OS
    Neurosci Res; 2003 Dec; 47(4):431-6. PubMed ID: 14630347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
    Barata-Antunes S; Teixeira FG; Mendes-Pinheiro B; Domingues AV; Vilaça-Faria H; Marote A; Silva D; Sousa RA; Salgado AJ
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
    Winkler C; Kirik D; Björklund A; Cenci MA
    Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The grid-walking test: assessment of sensorimotor deficits after moderate or severe dopamine depletion by 6-hydroxydopamine lesions in the dorsal striatum and medial forebrain bundle.
    Chao OY; Pum ME; Li JS; Huston JP
    Neuroscience; 2012 Jan; 202():318-25. PubMed ID: 22142899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.